Pacira Pharmaceuticals Price Target Raised to $60.00 at Barclays (PCRX)
Analysts at Barclays increased their target price on shares of Pacira Pharmaceuticals (NASDAQ:PCRX) from $56.00 to $60.00 in a research report issued to clients and investors on Friday, AmericanBankingNews.com reports. The firm currently has an “overweight” rating on the stock. Barclays’ price target would indicate a potential upside of 18.79% from the company’s current price.
A number of other firms have also recently commented on PCRX. Analysts at Wedbush raised their price target on shares of Pacira Pharmaceuticals from $43.00 to $59.00 in a research note to investors on Thursday, October 3rd. They now have an “outperform” rating on the stock. Separately, analysts at Brean Capital raised their price target on shares of Pacira Pharmaceuticals from $44.00 to $59.00 in a research note to investors on Thursday, October 3rd. They now have a “buy” rating on the stock. Finally, analysts at Jefferies Group raised their EPS on shares of Pacira Pharmaceuticals in a research note to investors on Tuesday, October 1st. They now have a “buy” rating and a $58.00 price target on the stock. They previously had a $44.00 price target on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $54.80.
Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) traded up 1.64% on Friday, hitting $51.34. The stock had a trading volume of 297,531 shares. Pacira Pharmaceuticals has a 1-year low of $15.07 and a 1-year high of $39.61. The stock has a 50-day moving average of $48.67 and a 200-day moving average of $36.11. The company’s market cap is $1.710 billion.
Pacira Pharmaceuticals (NASDAQ:PCRX) last released its earnings data on Thursday, October 31st. The company reported ($0.30) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.35) by $0.05. The company had revenue of $23.30 million for the quarter, compared to the consensus estimate of $22.10 million. On average, analysts predict that Pacira Pharmaceuticals will post $-1.70 earnings per share for the current fiscal year.
Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.